Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Stockholders held by Spero Therapeutics, Inc. on June 5, 2018. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions taken at the annual meeting.
Material Changes and Voting Results
A quorum of 9,585,075 shares (66.71% of the 14,369,182 eligible shares) was present. The following actions were ratified:
- Board of Directors: Casper Breum and David Southwell were reelected as Class I Directors until the 2021 annual meeting.
- Independent Auditor: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
| Director | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Casper Breum | 7,382,153 | 152,820 | 2,050,102 |
| David Southwell | 7,485,123 | 49,850 | 2,050,102 |
| Proposal | Votes For | Votes Against | Votes Abstained |
|---|---|---|---|
| Ratification of Auditor | 9,584,282 | 793 | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that PricewaterhouseCoopers LLP is the appointed auditor for the 2018 fiscal year.
- Verification of the tenure of the reelected Class I Directors (Casper Breum and David Southwell) through 2021.
- Review of the significant number of broker non-votes (2,050,102) regarding the director elections.